Horizon Therapeutics PLC
$
24.6
-0.97 (-3.79%)
| Volume: | 2,073,723 | Avg Vol (1m): | 1,993,715 |
| Market Cap $: | 4.55 Bil | Enterprise Value $: | 5.11 Bil |
| P/E (TTM): | 94.62 | P/B: | 2.82 |
| Earnings Power Value | 1.08 |
| Net Current Asset Value | -5.05 |
| Tangible Book | -4.64 |
| Projected FCF | 21.94 |
| Median P/S Value | 27.35 |
| Graham Number | 0 |
| Peter Lynch Value | 0 |
| DCF (FCF Based) | 0 |
| DCF (Earnings Based) | 0 |
1Y (-%)
Manual of Stocks™ Web
Financial Strength : 5/10
GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| Current | vs industry | vs history | |
|---|---|---|---|
| Cash-to-Debt | 0.65 |
Cash-To-Debt ranked
lower than
74.27%
of
859
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 91151, Med: 2.03, Min: -0.01
HZNP:
0.65
Ranked among companies with meaningful Cash-To-Debt only.
|
Cash-To-Debt range over the past 10 years
Min: 0.07, Med: 0.6, Max: 2.56
Current: 0.65
|
| Equity-to-Asset | 0.38 |
Equity-to-Asset ranked
lower than
91.50%
of
788
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 1.78, Med: 0.64, Min: -27.83
HZNP:
0.38
Ranked among companies with meaningful Equity-to-Asset only.
|
Equity-to-Asset range over the past 10 years
Min: -0.77, Med: 0.42, Max: 0.7
Current: 0.38
|
| Debt-to-Equity | 1.07 |
Debt-to-Equity ranked
lower than
95.81%
of
596
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 31.22, Med: 0.32, Min: 0.01
HZNP:
1.07
Ranked among companies with meaningful Debt-to-Equity only.
|
Debt-to-Equity range over the past 10 years
Min: -2.51, Med: 0.84, Max: 2.21
Current: 1.07
|
| Debt-to-EBITDA | 4.35 |
Debt-to-EBITDA ranked
lower than
97.78%
of
495
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 343059.67, Med: 1.92, Min: 0.01
HZNP:
4.35
Ranked among companies with meaningful Debt-to-EBITDA only.
|
Debt-to-EBITDA range over the past 10 years
Min: -24.41, Med: -0.42, Max: 13.54
Current: 4.35
|
| Interest Coverage | 0.82 |
Interest Coverage ranked
lower than
100.00%
of
648
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 2689668, Med: 86.08, Min: 0.01
HZNP:
0.82
Ranked among companies with meaningful Interest Coverage only.
|
Interest Coverage range over the past 10 years
Min: 0.08, Med: 0.44, Max: 0.82
Current: 0.82
|
| Piotroski F-Score | 8 |
0
1
2
3
4
5
6
7
8
9
| |
| Altman Z-Score | 1.37 |
DISTRESS
GREY
SAFE
| |
| Beneish M-Score | -2.92 |
Not Manipulator
Manipulator
| |
| WACC vs ROIC % |
ROIC 64.22%
WACC 6.99%
| ||
Profitability & Growth : 7/10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
| Current | vs industry | vs history | |
|---|---|---|---|
| Operating Margin % | 7.73 |
Operating Margin ranked
lower than
76.40%
of
801
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 8950, Med: 7.97, Min: -232970.37
HZNP:
7.73
Ranked among companies with meaningful Operating Margin only.
|
Operating Margin range over the past 10 years
Min: -1841.5, Med: -34.19, Max: 7.73
Current: 7.73
|
| Net Margin % | 3.98 |
Net Margin ranked
lower than
77.93%
of
802
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 304900, Med: 5.32, Min: -216285.19
HZNP:
3.98
Ranked among companies with meaningful Net Margin only.
|
Net Margin range over the past 10 years
Min: -1635.12, Med: -88.77, Max: 5.22
Current: 3.98
|
| ROE % | 4.84 |
ROE ranked
lower than
78.73%
of
832
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 316.96, Med: 5.94, Min: -3119.47
HZNP:
4.84
Ranked among companies with meaningful ROE only.
|
ROE range over the past 10 years
Min: -523.78, Med: -57.66, Max: 4.84
Current: 4.84
|
| ROA % | 1.25 |
ROA ranked
lower than
69.80%
of
871
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 943.36, Med: 2.88, Min: -1851.14
HZNP:
1.25
Ranked among companies with meaningful ROA only.
|
ROA range over the past 10 years
Min: -176.97, Med: -35.22, Max: 1.89
Current: 1.25
|
| ROC (Joel Greenblatt) % | 506.64 |
ROC (Joel Greenblatt) ranked
lower than
90.64%
of
855
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 34233.33, Med: 11.23, Min: -2671900
HZNP:
506.64
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
|
ROC (Joel Greenblatt) range over the past 10 years
Min: -3463.41, Med: -1393.9, Max: 520.88
Current: 506.64
|
| 3-Year Total Revenue Growth Rate | 16.80 |
3-Year Revenue Growth Rate ranked
higher than
86.65%
of
689
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 291.9, Med: 5.8, Min: -100
HZNP:
14.4
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
|
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: 18.3, Max: 115.5
Current: 14.4
|
| 3-Year Total EBITDA Growth Rate | 13.80 |
3-Year EBITDA Growth Rate ranked
lower than
100.00%
of
704
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 299.6, Med: 7.3, Min: -343.2
HZNP:
11.5
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
|
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: 5.75, Max: 73.2
Current: 11.5
|
» HZNP's 30-Y Financials
Financials (Next Earnings Date: 2019-08-08)
Guru Trades Click for details
Guru Trades in
SEC Filings
Gurus Latest Trades with NAS:HZNP
» Interactive Chart
Peter Lynch Chart
Business Description
| Industry | Drug Manufacturers » Drug Manufacturers - Specialty & Generic   NAICS : 325412   SIC : 2834 |
| Compare | BOM:532321 SHSE:600535 SZSE:000423 OHEL:ORNAV SZSE:300601 NAS:TLRY TSE:4516 LSE:HIK SHSE:600566 BSP:HYPE3 NYSE:TARO SHSE:603858 BOM:500257 SZSE:002773 TSX:CRON SZSE:000999 NYSE:AMRX BUD:RICHTER SHSE:600277 XTER:EVT |
| Traded in other countries | HPR.Germany |
| Address | 1 Burlington Road, Connaught House, 1st Floor, Dublin 4, IRL, D04 C5Y6 |
| Horizon Pharma is a specialty and generic drug manufacturing company. The company is focused on the identification, development, acquisition, and commercialization of differentiated and accessible medicines that address unmet medical needs. The overwhelming majority of revenue is generated in the United States. The company considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. | |
Ratios
| Current | vs industry | vs history | |
|---|---|---|---|
| PE Ratio (TTM) | 94.62 |
PE Ratio ranked
lower than
100.00%
of
557
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 1910, Med: 23.77, Min: 0.06
HZNP:
94.62
Ranked among companies with meaningful PE Ratio only.
|
PE Ratio range over the past 10 years
Min: 81.05, Med: 103.21, Max: 208.89
Current: 94.62
|
| Forward PE Ratio | 16.18 |
Forward P/E ranked
higher than
76.58%
of
111
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 322.58, Med: 21.6, Min: 5.03
HZNP:
16.18
Ranked among companies with meaningful Forward P/E only.
| N/A |
| PE Ratio without NRI | 94.62 |
PE without NRI ranked
lower than
100.00%
of
556
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 2125, Med: 24.2, Min: 0.06
HZNP:
94.62
Ranked among companies with meaningful PE without NRI only.
|
PE without NRI range over the past 10 years
Min: 81.05, Med: 103.21, Max: 208.89
Current: 94.62
|
| Price-to-Owner-Earnings | 30.99 |
Price-to-Owner-Earnings ranked
lower than
100.00%
of
324
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 3160, Med: 31.95, Min: 0.17
HZNP:
30.99
Ranked among companies with meaningful Price-to-Owner-Earnings only.
|
Price-to-Owner-Earnings range over the past 10 years
Min: 15.02, Med: 24.34, Max: 35.49
Current: 30.99
|
| PB Ratio | 2.82 |
PB Ratio ranked
lower than
68.25%
of
819
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 227.39, Med: 2.64, Min: 0.05
HZNP:
2.82
Ranked among companies with meaningful PB Ratio only.
|
PB Ratio range over the past 10 years
Min: 0.8, Med: 2.35, Max: 14.94
Current: 2.82
|
| PS Ratio | 3.27 |
PS Ratio ranked
lower than
51.61%
of
775
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 9105.26, Med: 3.1, Min: 0.03
HZNP:
3.27
Ranked among companies with meaningful PS Ratio only.
|
PS Ratio range over the past 10 years
Min: 1.47, Med: 3.66, Max: 19
Current: 3.27
|
| Price-to-Free-Cash-Flow | 13.59 |
Price-to-Free-Cash-Flow ranked
higher than
73.83%
of
298
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 3143.75, Med: 30.84, Min: 0.23
HZNP:
13.59
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
|
Price-to-Free-Cash-Flow range over the past 10 years
Min: 4.96, Med: 12.69, Max: 433
Current: 13.59
|
| Price-to-Operating-Cash-Flow | 13.33 |
Price-to-Operating-Cash-Flow ranked
higher than
64.29%
of
392
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 14229.87, Med: 22, Min: 0.23
HZNP:
13.33
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
|
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 4.84, Med: 11.71, Max: 209.52
Current: 13.33
|
| EV-to-EBIT | 52.37 |
EV-to-EBIT ranked
lower than
100.00%
of
572
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 1015380.11, Med: 17.85, Min: 0.13
HZNP:
52.37
Ranked among companies with meaningful EV-to-EBIT only.
|
EV-to-EBIT range over the past 10 years
Min: -775.4, Med: -4.4, Max: 302.9
Current: 52.37
|
| EV-to-EBITDA | 13.84 |
EV-to-EBITDA ranked
lower than
89.95%
of
597
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 341528.02, Med: 15.24, Min: 0.12
HZNP:
13.84
Ranked among companies with meaningful EV-to-EBITDA only.
|
EV-to-EBITDA range over the past 10 years
Min: -608, Med: -0.6, Max: 518
Current: 13.84
|
| EV-to-Revenue | 4.01 |
EV-to-Revenue ranked
lower than
59.37%
of
795
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 23858.8, Med: 3.24, Min: 0.03
HZNP:
4.01
Ranked among companies with meaningful EV-to-Revenue only.
|
EV-to-Revenue range over the past 10 years
Min: 0.5, Med: 4.4, Max: 30.2
Current: 4.01
|
| Current Ratio | 1.74 |
Current Ratio ranked
lower than
65.38%
of
855
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 413.44, Med: 2.39, Min: 0.02
HZNP:
1.74
Ranked among companies with meaningful Current Ratio only.
|
Current Ratio range over the past 10 years
Min: 0.16, Med: 1.74, Max: 4.39
Current: 1.74
|
| Quick Ratio | 1.68 |
Quick Ratio ranked
lower than
55.56%
of
855
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 413.44, Med: 1.87, Min: 0.02
HZNP:
1.68
Ranked among companies with meaningful Quick Ratio only.
|
Quick Ratio range over the past 10 years
Min: 0.16, Med: 1.62, Max: 4.27
Current: 1.68
|
| Days Inventory | 52.38 |
Days Inventory ranked
higher than
81.06%
of
755
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 950.68, Med: 119.8, Min: 0.2
HZNP:
52.38
Ranked among companies with meaningful Days Inventory only.
|
Days Inventory range over the past 10 years
Min: 13.1, Med: 71.61, Max: 201.46
Current: 52.38
|
| Days Sales Outstanding | 116.62 |
Days Sales Outstanding ranked
lower than
81.56%
of
770
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 864.61, Med: 81.76, Min: 0.1
HZNP:
116.62
Ranked among companies with meaningful Days Sales Outstanding only.
|
Days Sales Outstanding range over the past 10 years
Min: 67.08, Med: 101.46, Max: 140.47
Current: 116.62
|
| Days Payable | 33.74 |
Days Payable ranked
lower than
89.97%
of
758
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 952.38, Med: 76.32, Min: 0.04
HZNP:
33.74
Ranked among companies with meaningful Days Payable only.
|
Days Payable range over the past 10 years
Min: 23.56, Med: 97.38, Max: 410.36
Current: 33.74
|
Dividend & Buy Back
| Current | vs industry | vs history | |
|---|---|---|---|
| 3-Year Share Buyback Rate | -1.60 |
3-Year Share Buyback Rate ranked
lower than
61.30%
of
571
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 100, Med: -5.3, Min: -815
HZNP:
-1.6
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
|
3-Year Share Buyback Rate range over the past 10 years
Min: -428.1, Med: -61.1, Max: -1.6
Current: -1.6
|
Valuation & Return
| Current | vs industry | vs history | |
|---|---|---|---|
| Price-to-Projected-FCF | 1.12 |
Price-to-Intrinsic-Value-Projected-FCF ranked
higher than
68.98%
of
374
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 209, Med: 2.11, Min: 0.05
HZNP:
1.12
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
|
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 0.93, Med: 1.32, Max: 29.51
Current: 1.12
|
| Price-to-Median-PS-Value | 0.90 |
Price-to-Median-PS-Value ranked
higher than
59.22%
of
743
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 238.36, Med: 0.94, Min: 0.01
HZNP:
0.9
Ranked among companies with meaningful Price-to-Median-PS-Value only.
|
Price-to-Median-PS-Value range over the past 10 years
Min: 0.48, Med: 0.97, Max: 4.63
Current: 0.9
|
| Earnings Yield (Joel Greenblatt) % | 1.87 |
Earnings Yield (Greenblatt) ranked
lower than
75.20%
of
867
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 769.23, Med: 3.31, Min: -333.33
HZNP:
1.87
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
|
Earnings Yield (Greenblatt) range over the past 10 years
Min: -913.1, Med: -4.1, Max: 2.6
Current: 1.87
|
More Statistics
| Revenue (TTM) (Mil) $ | 1,264.06 |
| EPS (TTM) $ | 0.26 |
| Beta | 1.19 |
| Volatility % | 47.86 |
| 52-Week Range $ | 14.89 - 29.44 |
| Shares Outstanding (Mil) | 184.88 |
Analyst Estimate
Piotroski F-Score Details
| Piotroski F-Score | 8 |
| Positive ROA | Y |
| Positive CFROA | Y |
| Higher ROA yoy | Y |
| CFROA > ROA | Y |
| Lower Leverage yoy | Y |
| Higher Current Ratio yoy | Y |
| Less Shares Outstanding yoy | N |
| Higher Gross Margin yoy | Y |
| Higher Asset Turnover yoy | Y |